[1]FU R Q，MENG D S，CHEN L. Analysis of utility and monitoring of cyclosporine A after renal transplantation[J].Chin Hosp Pharm J(中国医院药学杂志)，2003，23(3)：160-161. [2]CITTERIO F. Evolution of the therapeutic drug monitoring of cyclosporine[J].Transplant Proc，2004，36(2 Suppl)：420S-425S. [3]SINGH D，KIBERD B，BELITSKY P，et al. Therapeutic monitoring of cyclosporine in kidney transplantation： the Halifax experience[J]. Transplant Proc，2004，36(2 Suppl)：414S-419S. [4]LANGERS P，CREMERS S C，DEN HARTIGH J，et al. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients[J].Liver Transpl，2004，10(2)：183-189. [5]QIAN F，WANG H，ZHU Y H，et al. Comparison between ρ2 and ρ0 as a monitoring tool for domestic cyclosporine A microemulsion capsule[J].Chin J Organ Transplant(中华器官移植杂志)，2003，24(5)：281-283. [6]ZHU T Y，SHI Y，JIANG J G，et al. Retrospective study of two-hour post-dose cyclosporine level(ρ2) monitoring in long term maintenance phase of renal transplant recipients[J].Chin J Organ Transplant(中华器官移植杂志)，2004，25(1)：25-27. [7]ZHU X D，HUANG F Q，LIU L，et al. Concentration-time curve of liver transplant recipients oraling neoral[J].Chin Hosp Pharm J(中国医院药学杂志)，2003，23(9)：541-542. [8]DING J J，JIAO Z，LI Z D，et al. Estimation areas under the curve after oral administration cyclosporine A in healthy volunteers by limited sampling strategy[J].Chin J Clin Pharmacol(中国临床药理学杂志)，2005，21(2)：154-157. [9]QIU S，LIU L，ZHAO L M，et al. Neoral ρ2 predicting drug hepatic toxicity following renal transplantation inhepatitis patients[J].Chin J Organ Transplant(中华器官移植杂志)，2003，24(1)：26-27. [10]TOKUI K，KIMATA T，UCHIDA K，et al. Dose adjustment strategy for oral microemulsion formulation of cyclosporine： population pharmacokinetics-based analysis in kidney transplant patients[J].Ther Drug Monit，2004，26(3)：287-294.